Finally, japanese researcher, dr masayo takahashi is leading a clinical trial in japan which transplants rpe cells made from ips cells into patients with wet amd. Having followed closely the developments in programs using pluripotent based therapeutics i was fortunate during isscr2015 to have the opportunity to sit down with dr masayo takahashi to discuss her pioneering efforts to translate shinya yamanakas groundbreaking. After 5 days of coculture, the activity of the immune cells against the target rpe cells was evaluated by the proliferation of the immune cells. Rpe sheet showed no sign of immune rejection during the one. Cell implants, genetic therapy, even optogenetics are. Nobelprizewinning stemcell researcher delivers keynote at. Human embryonic and induced pluripotent stem cells hesc and hipsc have tremendous potential for clinical implementation. Stem cell biotech biotime announced the news today that its subsidiary cell cure neurosciences cell cure has filed an ind with the fda for an embryonic stem es cellbased therapy for dry agerelated macular degeneration amd. Dec 12, 2019 the retina is the main visual sensory tissue in mammals. His collaborator on this trial, masayo takahashi of the riken center for developmental biology in kobe, japan, had a head start. Hoshimi kanemura, noriko sakai, masayo takahashi and masahiro j. The scientists at ucl have established a formal collaboration with pfizer for clinical development of a small patch of cells to cover the damaged macula, protecting the eye from agerelated blindness. Fabricating retinal pigment epithelial cell sheets derived. She is the first of six people taking part in the landmark treatment developed by masayo takahashi and her colleagues at the riken center for.
Here we show an optimized culture method for 3dretina generation from feederfree human pluripotent stem cells. Stem cells used in landmark therapy for failing sight new. We previously reported a technique for generating retinal pigment epithelia rpe and putative photoreceptors from embryonic stem es cells. Feb 10, 2011 retinitis pigmentosa rp is the most common inherited human eye disease resulting in night blindness and visual defects. The world economic forum is an independent international organization committed to improving the state of the world by engaging business, political, academic and other leaders of society to shape global, regional and industry agendas. Masayo takahashi which transplants rpe cells derived from ips cells into people with wet amd. On the basis of the good results of preclinical studies, such as those on the use of subretinal ipscderived rpe in mice demonstrated by li et al. Preconditioning the initial state of feederfree human pluripotent stem cells promotes selfformation of threedimensional retinal tissue. Clinicalgrade stem cellderived retinal pigment epithelium.
An engineered patch of retinal pigment epithelium generated from human embryonic stem cells is transplanted into the eyes of two patients. From the animal data it is clear that ipsc are rapidly becoming the lead cell type for cell replacement therapy and for the newly developing field of ipscderived body organ. In these cases, blood vessels in the eye grow abnormally and lead to bleeding, the destruction of rpe cells, and eventual blindness. Jan 23, 2017 in this interview, masayo takahashi, project leader for laboratory for retinal regeneration, riken center for developmental biology kobe, japan explains the techniques being utilized in the first induced pluripotent stem cell ipsc clinical trial in humans. Characterization of human induced pluripotent stem cellderived retinal pigment epithelium cell sheets aiming for clinical application author links open overlay panel hiroyuki kamao 1 2 michiko mandai 1 satoshi okamoto 1 noriko sakai 1 akiko suga 1 sunao sugita 1 junichi kiryu 2 masayo takahashi 1. Phase 1 clinical study of an embryonic stem cellderived. Sep 12, 2014 a japanese woman in her 70s is the first person to receive tissue derived from induced pluripotent stem cells, a technology that has created great expectations since it could offer the same. Typical in vitrobased assays rely on treatment of clones by media containing growth factors that promote cell specification, for example, activin a, bmp4 and wnt3a, in the presence or absence of fbs without basic fgf. Conventional thinking on diabetic retinopathy turned upside down. However, a more ambitious goal is to develop cell therapeutics using hpscs to generate and replace somatic cells that are lost as a result of disease or injury. Masayo takahashi is a pioneer in pushing the technology of ips cellderived cell types and actually introducing them into people. Evaluation of transplanted autologous induced pluripotent.
The advancement of human pluripotent stem cellderived. Preconditioning the initial state of feederfree human. Within 4 to 6 days, the cells are tested for gene and protein expression in embryonic lineages, including the classical markers pax6, brachyury and sox17 ectoderm, mesoderm and. Autologous induced stemcellderived retinal cells for. Easily share your publications and get them in front of issuus. Transplantation of autologous induced pluripotent stem cellderived retinal pigment epithelium cell sheets for exudative age related.
Nobelprizewinning stemcell researcher delivers keynote. Modeling retinal degeneration using patientspecific induced. Detection of retinal pigment epitheliumspecific antibody in. Once the photo receptor cells have been lost, only the cell transplantation will cure. Sep 15, 2014 the patient is part of the clinical study of autologous induced pluripotent stem cellderived retinal pigment epithelium rpe cell sheets for exudative amd, which is led by the riken cdbs masayo takahashi, m. Clinical studies using stem cells for treatment of retinal. The major objective was to assess safety, viability, and side effects.
To establish customized cell therapies originated from patients own cells, a group in japan led by masayo takahashi at the riken centre for developmental biology have relied on reprogramming cells from skin fibroblasts into induced pluripotent stem ips cells and then right into rpe. Jan 16, 2019 autologous induced pluripotent stem cell ipscderived retinal pigment epithelium rpe transplantation has been shown to improve visual function in animal models of agerelated macular degeneration amd and is currently being tested in human patients. Modeling retinal degeneration using patientspecific. Where do things stand with ips cell translational research. Mar 19, 2018 an engineered patch of retinal pigment epithelium generated from human embryonic stem cells is transplanted into the eyes of two patients. Last week, the woman, who is in her 70s, had a patch of the cells measuring 1. The retinal pigment epithelium rpe is a single layer of cells that supports the lightsensitive photoreceptor cells that are essential for retinal. The developers also used a coated, synthetic membrane on which they assembled rpe cells differentiated from human escs and surgically delivered the patch. Her mission is to cure diseases of blindness using ips cell technology. Treating macular degeneration amd with stem cells to save. It is considered an immune privileged site, and the number of cells needed for therapy is relatively low for the area of focused vision macula.
Stem cell transplantation to treat macular degeneration amdf. Gamm is working on a patch comprised of both photoreceptors and rpe to potentially restore vision to people with advanced retinal conditions. Treating macular degeneration amd with stem cells to. Masayo takahashi is doing pioneering work using pluripotent stem cells as a basis for helping patients with vision loss such as due to macular degeneration. Japanese woman is first recipient of nextgeneration stem. Jun 14, 2017 when she entered medicine in the mid1980s, masayo takahashi chose ophthalmology as her specialty, she said, because she wanted to have a family and thought the discipline would spare her from. Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. Masayo takahashi has been stopped reports the wsj in japan. After an assistant professor in the department of ophthalmology, kyoto university hospital, she moved to the salk institute in 1995, where she discovered the potential of stem cells as a tool for retinal therapy. Due to concerns about mutations and regulatory changes in japan, the trial was put on hold for several months. Masayo takahashi world alliance forum in san francisco. However, oncogenic mutations might occur during the cell reprogramming process. Takahashi and her team were investigating the safety of ipscderived cell sheets in patients with wettype agerelated macular degeneration.
To establish customized cell therapies originated from patients own cells, a group in japan led by masayo takahashi at the riken centre for developmental biology have relied on reprogramming cells from skin fibroblasts into induced pluripotent stem ips cells and then right into rpe cells. She is a faculty member at the riken centre for developmental biology, a prominent female scientist in japan, and a bona fide stem cell champion. A strategy for personalized treatment of ipsretinal. The trial was put on hold for several months due to regulatory changes in japan and concerns about mutations in an ips cell product to be used in the trial. An ophthalmologist, takahashi was familiar with the ravages of amd, a condition that progressively damages the macula, the central part of the retina, and is the leading cause of blindness in the elderly. It is well known that the disease is caused by rod photoreceptor degeneration. Masayo takahashi, who led the worlds first operation to implant induced pluripotent stem ips cells into a human body, says greater japanese understanding of the risks and benefits of new. We report here that sdia induces efficient neural differentiation also in primate embryonic stem cells. Treating ipscs with wnt and nodal antagonists in suspension culture induced expression of markers of retinal.
Retinal regeneration center for developmental biology. Finally, in september 2015, cdi again strengthened its ips cell therapy capacity by setting up a new venture, opsis therapeutics. Rpe consists of a monolayer of cells situated between the photoreceptors and the choroid, and plays essential roles in photoreceptor. Photoreceptors or rods and cones enable us to see in day or night. She is the first of six people taking part in the landmark treatment developed by masayo takahashi and her colleagues at the riken center for developmental biology in kobe, japan. Harnessing the potential of stem cells to cure vision loss. This spotlight article will describe the state of progress of some of the hpscderived.
Characterization of human induced pluripotent stem cell. Project leader, laboratory for retinal regeneration in collaboration with the institute for biomedical research and. The retina has been called the approachable part of the brain, owing to its relatively simple structure and its location near the body surface, and for these reasons it serves as a useful and experimentally amenable model of the central nervous system. The first trial in man using ips cells as a starting source for a cell therapy commenced in japan in 2014. Assessment of safety and functional efficacy of stem cell. Technological developments are required to overcome this, including automation instead of manual culture. The eye represents an ideal microenvironment for stem cellbased therapy. Treating macular degeneration amd with stem cells to save failing vision. Project leader masayo takahashi, md, explained that the woman had already failed at existing treatments.
Masao takahashi june 24, 1929 february 14, 2020 was a canadian judoka, author, coach, and founder of the takahashi school of martial arts est. In 2014, japanese researchers led by masayo takahashi became the first to treat the wet form of amda severe type of amd that afflicts retinal blood vesselsby implanting scaffoldless sheets of rpe derived from induced pluripotent stem ips cells. The newest development is that regulators in japan just have given conditional approval to an osaka university team to. To report the results after 4 years of followup in a previously presented first case of induced pluripotent stem cell ipscderived retinal pigment epithelium rpe sheet autologous. Stem cells used in landmark therapy for failing sight. Pdf stemming retinal regeneration with pluripotent stem. Cell and gene therapy insights cell and gene therapies. The authors showed that mice with retinal neuronal deficiency of aldh1a1 exhibited decreased vegf and sox9 production in rpe retinal pigment epithelium, and dorsal choroidal hypoplasia, which was phenocopied in mice with radeficient diet and also in mutant mice with rpe specific loss of sox9.
Since the discovery of induced pluripotent stem cells ipsc in 2006, the symptoms of many human diseases have been reversed in animal models with ipsc therapy, setting the stage for future clinical development. Developing rods transplanted into the degenerating retina. Retinitis pigmentosa rp is the most common inherited human eye disease resulting in night blindness and visual defects. However, to our knowledge, b cell invasion and antibody in the inflamed retina after transplantation of retinal pigment epithelial rpe cells has not been reported. A threedimensional retinal tissue 3dretina is a promising graft source for retinal transplantation therapy. Human embryonic and induced pluripotent stem cells in.
We previously demonstrated that embryonic stem cells escs can generate 3dretina in vitro using a selforganizing stem cell culture technique known as sfebq. View the profiles of people named masayo takahashi. Shes the very first person in the world to successfully overcome all the regulatory barriers and the scientific barriers to introduce this new type of stem cell into a patient. The ogawayamanaka prize prize is meant to incentivize and honor those whose work is advancing the translational use of stem cells for regenerative medicine. Sep 17, 2014 stem cells used in landmark therapy for failing sight. Incorporated as a notforprofit foundation in 1971, and headquartered in geneva, switzerland, the forum is tied to no political, partisan or national interests. Retinal regeneration center for developmental biology riken cdb. It is characterized by a progressive loss of photoreceptors in the macula due to damage to the retinal pigment epithelium rpe. It was a major thrill to have a nobelprizewinning scientist speak to our community, says stephen rose, ph.
Autologous induced pluripotent stem cell ipscderived retinal pigment epithelium rpe transplantation has been shown to improve visual function in animal models of agerelated macular degeneration amd and is currently being tested in human patients. Agerelated macular regeneration amd is a refractory ocular disease that causes severe deterioration in central vision due to senescence in the retinal pigment epithelium rpe. A japanese lady in her 70s was the first patient to be treated by masayo takahashi and her team at the riken center for developmental biology kobe, japan. Nov 14, 2017 antibodymediated rejection is characterized by donorspecific antibody produced by b cells. It has since recommenced in june 2016 and many await the findings.
We assessed the feasibility of transplanting a sheet of retinal pigment epithelial rpe cells differentiated from induced pluripotent stem cells ipscs in a patient with neovascular agerelated m. Transplantation of ipscderived rpe sheet into first amd. Our research into retinal regeneration seeks to achieve clinical applications by developing methods for inducing stem cells or embryonic stem cells to differentiate into retinal neurons and pigment epithelial cells in sufficient. There is another clinical trial in japan led by japanese researcher dr. Kuwahara a, yamasaki s, mandai m, watari k, matsushita k, fujiwara m, hori y, hiramine y, nukaya d, iwata m, kishino a, takahashi m, sasai y, kimura t. Masao takahashi agenda contributor world economic forum. He was involved in judo for more than 70 years, and was ranked hachidan eighthdegree black belt, making him one of the highest ranked canadian judoka. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. Jun 19, 2016 retina specialist focuses on the latest advances in the diagnosis, medical management and surgical treatment of diseases of the retina, along with practical, realworld advice from leading clinicians and other experts on managing the successful retina practice. Prospects for clinical use of reprogrammed cells for. In spite of all hurdles and controversy, clinical trials in treatment of spinal cord injury, macular degeneration of retina, type 1 diabetes and heart failure are already ongoing. Conventional thinking on diabetic retinopathy turned. Jul 01, 2015 the pioneering induced pluripotent stem cell ipsc clinical study in japan led by top stem cell clinical researcher dr.
Antibodymediated rejection is characterized by donorspecific antibody produced by b cells. Here we tested whether our procedure can promote retinal differentiation of mouse and human induced pluripotent stem cells ipscs. The study uses autologous ips cells to derive rpes. Neural retinaspecific aldh1a1 controls dorsal choroidal. Join facebook to connect with masayo takahashi and others you may know.
Retinal pigment epithelial or rpe cells nourish the rods and cones. Opsis is focused on discovering and developing novel medicines to treat retinal diseases and is a partnership with dr. Masayo takahashi, professor, riken center for biosystems dynamics research masayo takahashi received her m. During retinal development, the optic cup derived from the rostral diencephalon is composed of inner and outer walls that differentiate into the neural retina nr and retinal pigment epithelium rpe, respectively. Agerelated macular degeneration amd bressler et al. Facebook gives people the power to share and makes the world more open and connected. Generation of dopaminergic neurons and pigmented epithelia. The trial was put on hold for several months due to regulatory changes in japan and concerns about mutations in an ips cell product to be used in.
Clegg discusses stem cell therapies for eye disease. These cells were investigated by action potential analysis with manual and automatic planar patch clamp. The pioneering induced pluripotent stem cell ipsc clinical study in japan led by top stem cell clinical researcher dr. Recently, ips cells from retinitis pigmentosa rp and gyrate atrophy patients were differentiated into rods and rpe and used to test the effects of drugs. Detection of retinal pigment epitheliumspecific antibody. David gamm, the pioneer of ips cellderived retinal differentiation and transplantation. Masayo takahashi, takahashi masayo, born june 23, 1961 is a japanese medical physician, ophthalmologist and stem cell researcher takahashi serves as a project research leader at the riken center for developmental biology in kobe focusing on the clinical application of ips cell induced pluripotent stem cell technology on macular degeneration. Generation of retinal cells from mouse and human induced.
979 1080 668 142 579 1305 1290 991 858 603 1521 638 1049 145 1309 373 1240 893 1040 639 680 1102 1295 1423 139 1096 1167 369 118 635 303 1018 925 491 1311 1455 311 378 1350 928 954 972 559 1026 1494 971 453